A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

Multiple Myeloma Clinical Trial

Official title:

Belantamab Mafodotin in Combination With Nirogacestat in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05276141
• Other study ID #: 21-495
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: March 31, 2022
• Est. completion date: March 2024

Study information

• Verified date: March 2022
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Malin Hultcrantz, MD, PhD
• Phone: 646-608-3714
• Email: hultcram[@]mskcc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out whether combination treatment with the study drugs belantamab mafodotin and nirogacestat is a safe treatment for people who have relapsed or refractory multiple myeloma. The researchers will test different doses of belantamab mafodotin to find the safest dose to give with nirogacestat. They also want to find out whether belantamab mafodotin plus nirogacestat is an effective treatment for this type of bone marrow cancer, and will do tests that show whether the study treatment slows or stops the growth of cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with relapsed or refractory multiple myeloma treated with 3 or more prior lines of therapy. Relapsed/refractory multiple myeloma is defined by the International Myeloma Working Group (IMWG) updated criteria.

• Patients need to have measurable disease defined by one or more of the following:

1. Serum myeloma (M)-protein greater than or equal to 0.5 g/dL (5 g/L).

2. Urine M-protein greater or equal to 200 mg/24 h.

3. Involved light chain (either kappa or lambda) is >10 mg/dL with an abnormal kappa:

lambda ratio.

4. A biopsy proven plasmacytoma(s) that is new or definitely increased. Increase is defined as a 50% and at least 1 cm increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion.

5. A bone marrow biopsy demonstrating >30% infiltration of clonal plasma cells.

• Have undergone autologous stem cell transplant or are considered transplant ineligible.

• Patients who have received prior CAR T cells are eligible. Patients who have received prior BCMA-directed therapy, other than belantamab mafodotin, are eligible. Patients who have received prior allogeneic stem cell transplantation >100 days prior are eligible.

• Female or male patients age =18 years.

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2. PS-3 is permitted if PS is due solely to bone pain.

• Fulfil the criteria for Adequate Organ System Function Based on Safety Assessments

°Hematologic

• Absolute neutrophil count (ANC)a =1.0 × 10^9/L

• Hemoglobin a =8.0 g/dL

• Platelets a =50 × 109/L

°Hepatic

• Total bilirubin =1.5 × ULN; (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)

• ALT = 2.5 × ULN

°Renal

• eGFRb =30 mL/min/1.73 m^2

• Spot urine (albumin/creatinine ratio from spot urine) = 500 mg/g (56 mg/mmol) OR Urine dipstick Negative/trace (if ³1+ only eligible if confirmed <500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void)

°Cardiac

• Left Ventricular Ejection Fraction (LVEF) by ECHO =40% Note: Laboratory results obtained during Screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the Investigator may re-test the participant and the subsequent within range screening result may be used to confirm eligibility.

1. Without Growth factor support for the past 14 days, excluding erythropoietin. Transfusions are allowed

2. As calculated by Modified Diet in Renal Disease (MDRD) formula.

• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade = 1, with the exception of peripheral neuropathy attributable to bortezomib.

• Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

°Is not a woman of childbearing potential (WOCBP)

• Nonchildbearing potential is defined as follows (by other than medical reasons):

• 45 years of age and has not had menses for >1 year

• Patients who have been amenorrhoeic for <2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation

• Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.

OR

• Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency, during the intervention period and for at least 6 months after the last dose of study intervention.

• WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to treatment with nirogacestat and must agree to use a highly effective method of contraception (i.e. copper-containing intrauterine device, established use of oral, inserted, injected or implanted hormonal method of contraception, or male/female sterilization, etc.)

• WOCBP must agree not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.

• Male participants: Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm: Male patients must use a condom when having sexual intercourse with a woman of childbearing potential (WOCBP) while receiving treatment with nirogacestat and for at least 6 months after the last dose. An additional form of highly effective contraception should also be used by the female partner, if of child-bearing potential

• Signed and dated Informed Consent by study participant.

• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures.

Exclusion Criteria:

• Prior treatment with belantamab mafodotin

• Systemic anti-myeloma therapy (including systemic steroids) within =14 days, or plasmapheresis within 7 days prior to the first dose of study drug.

• Use of an investigational drug within 14 days or five half-lives (whichever is longer) preceding the first dose of study drug.

• Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs.

• Radiation therapy within 2 weeks prior to study entry (bone lesions requiring radiation may be treated with limited [i.e., = 25% of bone marrow in field] radiation therapy during this period).

• Patients with a history of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment.

• Participant must not have had major surgery =4 weeks prior to initiating study treatment.

• Evidence of active mucosal or internal bleeding.

• Presence of active renal condition (infection or requirement for dialysis). Participants with isolated proteinuria resulting from multiple myeloma are eligible, provided they fulfill criteria given

• Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease per investigator's assessment).

• Participants with invasive malignancies other than multiple myeloma are excluded, unless the second malignancy has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease with the exceptions of successfully treated non-metastatic basal cell, squamous cell skin carcinoma, or in-situ carcinoma.

• Evidence of cardiovascular risk including any of the following:

• Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.

• History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening

• Class III or IV heart failure as defined by the New York Heart Association functional classification system.

• Uncontrolled hypertension

• Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia (e.g., quinidine, procainamide, disopromide) and Class III (e.g., dofetilide, ibutilide, sotalol) antiarrhythmics at the time of informed consent. Non-antiarrhythmic medications which may prolong the QT/QTcF interval are allowed provided the participant does not have additional risk factors for Torsades de Pointes (TdP).

• Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.

• Pregnant or lactating female.

• Active infection requiring treatment.

• Participant has known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria:

1. Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load <400 copies/mL, and

2. CD4+ T-cell (CD4+) counts =350 cells/µL, and

3. No history of acquired immunodeficiency s-defining opportunistic infections within the last 12 months.

Note: Consideration must be given to ART and prophylactic antimicrobials that may have a drug-drug interaction and/or overlapping toxicities with belantamab mafodotin or other combination products as relevant.

• Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at Screening or within 3 months prior to first dose of study treatment). Note: Participants with positive Hepatitis B antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis B RNA test is obtained.

• Positive hepatitis C antibody test result or positive hepatitis C RNA test result at Screening or within 3 months prior to first dose of study treatment. Note: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing

• Current corneal disease except for mild punctate keratopathy. Note: Participants with mild punctate keratopathy are allowed.

• Participant must not use contact lenses while participating in this study.

• Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.

• Study participant has known malabsorption syndrome or preexisting gastrointestinal conditions that may impair absorption of nirogacestat (e.g., gastric bypass, lap band, or other gastric procedures that would alter absorption); delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed.

• Concomitant administration of a strong or moderate CYP3A4 inhibitor or inducer within 14 days prior to first dose of nirogacestat (this may need to be expended to include the food that are prohibited).Please note that strong or moderate CYP3A inhibitor or inducer administration is to be prohibited during participation on study.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Belantamab Mafodotin
Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.4 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. The first 3 patients will be treated at the first dose level 1.4 mg/kg. If there are no dose limiting toxicities, the dose will be increased to 1.9 mg/kg for the coming 3 patients and subsequently to 2.5 mg/kg per dose escalation
• Nirogacestat
1:1 randomization between nirogacestat 100 mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100 mg BID continuously during each cycle for all subjects.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	New York

Sponsors (3)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	GlaxoSmithKline, SpringWorks Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)	The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized.	up to six weeks
Secondary	Clinical Response	Traditional Response Criteria from International Myeloma Working Group Criteria for Multiple Myeloma	2 years

External Links

•   Memorial Sloan Kettering Cancer Center